{"id":"subcutaneous-injection-of-secukinumab","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nasopharyngitis"},{"rate":"8-12","effect":"Upper respiratory tract infection"},{"rate":"5-8","effect":"Diarrhea"},{"rate":"4-7","effect":"Headache"},{"rate":"3-5","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1743068","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Secukinumab selectively binds to and neutralizes IL-17A, preventing its interaction with IL-17 receptors on immune and tissue cells. This inhibition reduces the recruitment and activation of neutrophils and other inflammatory cells, thereby suppressing the inflammatory cascade underlying autoimmune and inflammatory conditions. By targeting IL-17A specifically, it modulates the Th17 immune response without broadly suppressing the entire immune system.","oneSentence":"Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:08.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Non-radiographic axial spondyloarthritis"}]},"trialDetails":[{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT05722522","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-10","conditions":"Rotator Cuff Tendinopathy","enrollment":33},{"nctId":"NCT05380453","phase":"PHASE3","title":"Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-09-29","conditions":"Giant Cell Arteritis","enrollment":151},{"nctId":"NCT06630559","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-05-26","conditions":"Plaque Psoriasis","enrollment":153},{"nctId":"NCT05758415","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-02","conditions":"Rotator Cuff Tendinopathy","enrollment":60},{"nctId":"NCT07261072","phase":"PHASE4","title":"Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College","startDate":"2025-12-01","conditions":"Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab","enrollment":30},{"nctId":"NCT07254325","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2025-12-15","conditions":"Psoriasis","enrollment":114},{"nctId":"NCT03769168","phase":"PHASE3","title":"An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-07","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":55},{"nctId":"NCT06398652","phase":"PHASE3","title":"Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-08-27","conditions":"Psoriasis","enrollment":336},{"nctId":"NCT07140666","phase":"","title":"Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis","status":"COMPLETED","sponsor":"Chongli Yu","startDate":"2022-08-01","conditions":"Psoriasis","enrollment":100},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT07109765","phase":"","title":"Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2025-06-01","conditions":"Hidradenitis Suppurativa (HS)","enrollment":50},{"nctId":"NCT07054970","phase":"PHASE1","title":"To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2024-01-12","conditions":"Healthy Male Subjects","enrollment":172},{"nctId":"NCT06786936","phase":"","title":"Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms","status":"RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2025-06-02","conditions":"Psoriatic Arthritis, Depression, Psoriatic Plaque","enrollment":50},{"nctId":"NCT05215561","phase":"","title":"Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-02-14","conditions":"Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis","enrollment":36},{"nctId":"NCT04717466","phase":"PHASE4","title":"Brain Changes in Psoriasis After Secukinumab Treatment","status":"COMPLETED","sponsor":"University of Miami","startDate":"2021-06-29","conditions":"Psoriasis, Healthy","enrollment":20},{"nctId":"NCT05232864","phase":"PHASE3","title":"Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-22","conditions":"Lupus Nephritis","enrollment":31},{"nctId":"NCT05377944","phase":"PHASE3","title":"Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-10-26","conditions":"Plaque Psoriasis","enrollment":502},{"nctId":"NCT06833112","phase":"PHASE4","title":"Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2025-02","conditions":"Ankylosing Spondylitis","enrollment":10},{"nctId":"NCT06801028","phase":"","title":"Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2025-01-20","conditions":"Erythrodermic Psoriasis","enrollment":60},{"nctId":"NCT04737330","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-29","conditions":"Thyroid Eye Disease, Graves Orbitopathy","enrollment":28},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT04711902","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-24","conditions":"Psoriatic Arthritis","enrollment":41},{"nctId":"NCT04080661","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2018-03-22","conditions":"Psoriasis Vulgaris","enrollment":82},{"nctId":"NCT03791060","phase":"PHASE2","title":"Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2019-04-03","conditions":"Necrobiosis Lipoidica Diabeticorum","enrollment":4},{"nctId":"NCT05734482","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-02-15","conditions":"Psoriasis","enrollment":130},{"nctId":"NCT04102007","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-11-12","conditions":"Plaque Psoriasis","enrollment":244},{"nctId":"NCT02471144","phase":"PHASE3","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-29","conditions":"Chronic Severe Plaque-type Psoriasis","enrollment":162},{"nctId":"NCT04711343","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-06-08","conditions":"Psoriasis","enrollment":216},{"nctId":"NCT03765788","phase":"PHASE2","title":"A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-01-30","conditions":"Giant Cell Arteritis","enrollment":52},{"nctId":"NCT03440736","phase":"PHASE4","title":"Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-28","conditions":"Psoriasis, Metabolic Syndrome","enrollment":781},{"nctId":"NCT04571567","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Saakshi Khattri","startDate":"2019-12-02","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT03955861","phase":"","title":"Ultrasound Enthesitis Response in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2019-02-14","conditions":"Psoriatic Arthritis, Psoriasis, Enthesitis","enrollment":80},{"nctId":"NCT03307447","phase":"PHASE4","title":"Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).","status":"UNKNOWN","sponsor":"Narrows Institute for Biomedical Research","startDate":"2017-12-19","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT04996485","phase":"PHASE4","title":"Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children","status":"UNKNOWN","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2021-03-01","conditions":"Congenital Ichthyosis","enrollment":50},{"nctId":"NCT03478787","phase":"PHASE3","title":"Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-08","conditions":"Psoriasis","enrollment":327},{"nctId":"NCT03568136","phase":"PHASE2","title":"Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2018-09-18","conditions":"Dermatitis, Atopic, Eczema, Atopic, Neurodermatitis, Atopic","enrollment":22},{"nctId":"NCT03535194","phase":"PHASE3","title":"A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-06-26","conditions":"Psoriasis","enrollment":1484},{"nctId":"NCT02599129","phase":"PHASE2","title":"A Study of Secukinumab for the Treatment of Alopecia Areata","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-11","conditions":"Alopecia Areata","enrollment":11},{"nctId":"NCT04414605","phase":"EARLY_PHASE1","title":"Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2020-06-04","conditions":"Psoriasis","enrollment":10},{"nctId":"NCT02267135","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-09-29","conditions":"Chronic Scalp Psoriasis","enrollment":102},{"nctId":"NCT01365455","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-06","conditions":"Moderate to Severe Plaque-type Psoriasis","enrollment":738},{"nctId":"NCT01828086","phase":"PHASE1","title":"Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06","conditions":"Chronic Plaque-type Psoriasis","enrollment":95},{"nctId":"NCT02404350","phase":"PHASE3","title":"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-08-31","conditions":"Psoriatic Arthritis","enrollment":997},{"nctId":"NCT02854163","phase":"PHASE2","title":"Effect of Secukinumab in the Treatment of Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-10-15","conditions":"Psoriatic Arthritis","enrollment":30},{"nctId":"NCT01649375","phase":"PHASE3","title":"16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-18","conditions":"Anklyosing Spondylitis","enrollment":219},{"nctId":"NCT02750592","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-03-22","conditions":"Ankylosing Spondylitis","enrollment":30},{"nctId":"NCT02748863","phase":"PHASE3","title":"Study of Secukinumab With 2 mL Pre-filled Syringes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-12","conditions":"Psoriasis","enrollment":214},{"nctId":"NCT02294227","phase":"PHASE3","title":"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-29","conditions":"Arthritis, Psoriatic","enrollment":341},{"nctId":"NCT02594098","phase":"PHASE2","title":"Secukinumab for Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-11","conditions":"Atopic Dermatitis","enrollment":41},{"nctId":"NCT02394561","phase":"PHASE3","title":"A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-10","conditions":"Plaque Type Psorisis","enrollment":434},{"nctId":"NCT02159053","phase":"PHASE3","title":"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-18","conditions":"Spondylitis, Ankylosing","enrollment":350},{"nctId":"NCT01952015","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-21","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT02008890","phase":"PHASE3","title":"Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-26","conditions":"Palmoplantar Pustular Psoriasis","enrollment":237},{"nctId":"NCT02362789","phase":"PHASE3","title":"Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-01-04","conditions":"Psoriasis","enrollment":132},{"nctId":"NCT01636687","phase":"PHASE3","title":"Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-17","conditions":"Plaque-type Psoriasis","enrollment":182},{"nctId":"NCT02911857","phase":"PHASE3","title":"An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-03","conditions":"Periodic Fevers Syndrome","enrollment":4},{"nctId":"NCT01640951","phase":"PHASE3","title":"4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-09-16","conditions":"Moderate to Severe Chronic Plaque-Type Psoriasis","enrollment":675},{"nctId":"NCT02474082","phase":"PHASE3","title":"Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04","conditions":"Psoriasis","enrollment":202},{"nctId":"NCT02547714","phase":"PHASE4","title":"Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-16","conditions":"Plaque Psoriasis","enrollment":34},{"nctId":"NCT02074982","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-26","conditions":"Chronic Plaque Type Psoriasis","enrollment":676},{"nctId":"NCT00685399","phase":"PHASE2","title":"Safety and Efficacy of AIN457 in Noninfectious Uveitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06","conditions":"Non-infectious Uveitis","enrollment":76},{"nctId":"NCT02559622","phase":"PHASE3","title":"Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Psoriasis","enrollment":151},{"nctId":"NCT01770379","phase":"PHASE3","title":"Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":242},{"nctId":"NCT00995709","phase":"PHASE3","title":"Phase III Study in Refractory Behcet's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Behcet Disease","enrollment":118},{"nctId":"NCT01406938","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Moderate to Severe Plaque-type Psoriasis","enrollment":967},{"nctId":"NCT01412944","phase":"PHASE3","title":"Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-12","conditions":"Plaque-type Psoriasis","enrollment":43},{"nctId":"NCT01900782","phase":"PHASE3","title":"Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Psoriasis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":96,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Subcutaneous injection of Secukinumab","genericName":"Subcutaneous injection of Secukinumab","companyName":"Peking Union Medical College","companyId":"peking-union-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}